Of solid tumor patients do not respond to immune checkpoint inhibitor therapy
New mCRPC patients per year with cold tumors
Average survival for 3th-4th line mCRPC patients
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
